Leukapheresis using Amicus Separator

Overview

About this study

 

The purpose of this study is to determine if the device being used, the Amicus apheresis device, can perform effective leukapheresis procedures and be used instead of the COBE Spectra when it is no longer available.

 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Please contact the study team to discuss whether or not you are eligible to participate in a study.

Inclusion Criteria:

  • Patients will have presumed diagnosis of one of the following:
    • AML (Acute Myelogenous Leukemia) FAB classification M0, M1, M2, M3, M4, M5, M6, M7;
    • ALL (Acute Lymphocytic Leukemia);
    • CLL (Chronic Lymphocytic Leukemia);
    • CML (Chronic Myelogenous Leukemia).
  • Age 18 years old and older.

Exclusion Criteria:

  • Unstable blood pressure.
  • Electrolytes imbalance with clinical consequences. 
  • Known pregnancy. 
  • Age < 18 years.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Jeffrey Winters, M.D.

Open for enrollment

Contact information:

Page McCarthy

(507) 266-1294

McCarthy.Page@mayo.edu

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Jeffrey Winters, M.D.

Closed for enrollment

Contact information:

Page Abdelaty

(507)266-1294

Abdelaty.Page@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20304181

Mayo Clinic Footer